Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases

被引：11

作者：

Dauby, Nicolas ^{[1
]}

Van Praet, Serge ^{[2
]}

Vanhomwegen, Charlotte ^{[3
]}

Veliziotis, Ioannis ^{[3
]}

Konopnicki, Deborah ^{[1
]}

Roman, Alain ^{[3
]}

机构：

[1] Univ Libre Bruxelles, CHU St Pierre, Dept Infect Dis, Brussels, Belgium

[2] CHU St Pierre, Dept Pharm, Brussels, Belgium

[3] Univ Libre Bruxelles, Intens Care Unit, CHU St Pierre, Brussels, Belgium

来源：

JOURNAL OF MEDICAL VIROLOGY | 2021年 / 93卷 / 02期

关键词：

D O I：

10.1002/jmv.26488

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：689 / 691

页数：3

共 12 条

[1] RETRACTED: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study (Retracted Article) [J].

Cai, Qingxian ;

Yang, Minghui ;

Liu, Dongjing ;

Chen, Jun ;

Shu, Dan ;

Xia, Junxia ;

Liao, Xuejiao ;

Gu, Yuanbo ;

Cai, Qiue ;

Yang, Yang ;

Shen, Chenguang ;

Li, Xiaohe ;

Peng, Ling ;

Huang, Deliang ;

Zhang, Jing ;

Zhang, Shurong ;

Wang, Fuxiang ;

Liu, Jiaye ;

Chen, Li ;

Chen, Shuyan ;

Wang, Zhaoqin ;

Zhang, Zheng ;

Cao, Ruiyuan ;

Zhong, Wu ;

Liu, Yingxia ;

Liu, Lei .

ENGINEERING, 2020, 6 (10) :1192-1198

[2]

Chinello P, 2017, PLOS NEGLECT TROP DI, V11, DOI DOI 10.1371/JOURNAL.PNTD.0006034

[3] Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series [J].

Doi, Kent ;

Ikeda, Mahoko ;

Hayase, Naoki ;

Moriya, Kyoji ;

Morimura, Naoto .

CRITICAL CARE, 2020, 24 (01)

[4] Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection [J].

Du Yin-Xiao ;

Chen Xiao-Ping .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (02) :242-247

[5] Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2 [J].

Eloy, Philippine ;

Solas, Caroline ;

Touret, Franck ;

Mentre, France ;

Malvy, Denis ;

de Lamballerie, Xavier ;

Guedj, Jeremie .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (02) :188-188

[6] Favipiravir (T-705), a novel viral RNA polymerase inhibitor [J].

Furuta, Yousuke ;

Gowen, Brian B. ;

Takahashi, Kazumi ;

Shiraki, Kimiyasu ;

Smee, Donald F. ;

Barnard, Dale L. .

ANTIVIRAL RESEARCH, 2013, 100 (02) :446-454

[7] Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19 [J].

Irie, Kei ;

Nakagawa, Atsushi ;

Fujita, Hirotoshi ;

Tamura, Ryo ;

Eto, Masaaki ;

Ikesue, Hiroaki ;

Muroi, Nobuyuki ;

Tomii, Keisuke ;

Hashida, Tohru .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (05) :880-885

[8] The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers [J].

Malvy, Denis ;

Taburet, Anne-Marie ;

de Lamballerie, Xavier ;

Mentre, France ;

Extramiana, Fabrice .

PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (06) :1-4

[9] Cardiac effects and toxicity of chloroquine: a short update [J].

Mubagwa, Kanigula .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (02)

[10]

Pilkington V, 2020, J VIRUS ERAD, V6, P45

← 1 2 →